FDA announces public meeting to discuss gender differences in use and responses to CBD
The US Food and Drug Administration has announced a virtual public meeting to explore the potential sex (biological) and gender (psychosocial) differences in use and responses to cannabidiol (CBD) and other cannabinoids.